Silvio da Rocha Carvalho

Silvio da Rocha Carvalho

Auto-generated profile, based on publicly available information

Silvio da Rocha Carvalho

Serviço de Gastroenterologia Pediátrica Universidade Federal do Rio, de Janeiro Rio de Janeiro Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Revista Paulista de Pediatria
Verified
Journal Article
Open access
PDF file
TTThaís Moreno Tomé
Thaís Moreno Tomé
ALAna Beatriz de Menezes Lima
Ana Beatriz de Menezes Lima
JMJanaína Mezzonato Machado
Janaína Mezzonato Machado
MAMariana Tschoepke Aires
Mariana Tschoepke Aires
SCSilvio da Rocha Carvalho
Silvio da Rocha Carvalho
CFCarlos Fernando Francesconi
Carlos Fernando Francesconi
Objective: To describe the protocol used for translation and cross-cultural adaptation of the questionnaires developed by the Rome Foundation for the diagnosis of disorders of gut-brain interaction in the pediatric population.

26 March 2026 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
JOJane Oba
Jane Oba
CSCarlos Walter Sobrado
Carlos Walter Sobrado
ELElizete Aparecida Lomazi
Elizete Aparecida Lomazi
MDMariana Deboni
Mariana Deboni
MMMichela Cynthia da Rocha Marmo
Michela Cynthia da Rocha Marmo
CFClovis Artur Almeida da Silva Full
Clovis Artur Almeida da Silva Full
Objectives: Upper and small bowel Crohn's disease (U‐SBCD) represents a clinically aggressive phenotype with high complication rates yet remains diagnostically challenging. In low‐ and middle‐income countries (LMICs), limited inflammatory bowel disease (IBD) awareness contributes to diagnostic delays, but their impact on U‐SBCD outcomes remains poorly characterized. We aimed to characterize clinical features, management patterns, and surgical outcomes of pediatric U‐SBCD in Brazil, establishing IBD baseline for future regional comparisons in LMIC setting. Methods: This multicenter retrospective study analyzed 124 pediatric Crohn′s disease (CD) patients (diagnosed < 18 years) from six Brazilian centers according to revised PORTO‐European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) criteria. Patients with U‐SBCD (Paris L4a/L4b, n = 39) were compared to non‐SBCD (L1/L2/L3). Univariate and multivariable analyses assessed demographics, diagnostic delay, disease behavior, growth impairment, and therapeutic outcomes over 18 months follow‐up. The population comprised predominantly African–Brazilian admixture. Results: U‐SBCD patients presented at older age (median 14 vs. 12 years; p = 0.001) with greater height impairment ( p = 0.010) and lower body mass index (BMI)/age z ‐scores (−1.14 vs. −0.44; p = 0.029). Severe weight loss ( z ‐score < −2) conferred 8.3‐fold increased U‐SBCD odds (95% confidence interval [CI]: 2.17–31.66; p = 0.002). Each year of diagnostic delay increased U‐SBCD odds by 22% (95% CI: 1.06–1.39; p = 0.004). U‐SBCD patients required more biologic therapy (97% vs. 75%; p = 0.003) with higher treatment escalation rates (31.6% vs. 21.2%; p = 0.004). Multivariate analysis confirmed U‐SBCD as an independent three‐fold predictor of surgery (OR 3.02; 95% CI: 1.02–8.94; p = 0.046). A 9‐year‐old girl with U‐SBCD died perioperatively. Psychiatric symptoms affected 30% of both groups. Conclusion: In LMIC settings, strengthening medical education is essential to improve early recognition of U‐SBCD and prevent progression to irreversible complications. Notably, the phenotypic pattern observed in our study more closely resembled that reported in Asian pediatric patients than Caucasian cohorts.

1 January 2026 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
SCSilvio da Rocha Carvalho
Silvio da Rocha Carvalho
MAMariana Tschoepke Aires
Mariana Tschoepke Aires
JJJosé César da Fonseca Junqueira
José César da Fonseca Junqueira
RLRonir Luiz
Ronir Luiz
CLEMAX COUTO SANT´ANNACLEMAX COUTO SANT´ANNA
CLEMAX COUTO SANT´ANNA
Fecal calprotectin levels can be used to monitor inflammation and vary with age; those of children under 4 years of age should be carefully interpreted. This study aimed to analyze factors contributing to variations in fecal calprotectin levels of apparently healthy public and private schoolchildren aged 4-6 years. This study was conducted in Rio de Janeiro from 2019 to 2022. Fecal samples were obtained for parasitological examination and fecal calprotectin measurement. School category (public and private from regions with different socioeconomic levels), sex, and weight were compared. The mean and standard deviation for fecal calprotectin levels were determined using the Mann-Whitney U test. A total of 155 fecal samples were evaluated. The mean calprotectin levels in public and private schoolchildren were 57.1 μg/g and 18.0 μg/g, respectively (p < 0.03). The mean calprotectin levels were 57.5 μg/g and 12.4 μg/g in female public and private schoolchildren, respectively (p < 0.04). Fecal calprotectin levels were significantly different between children attending public and private schools potentially due to varying degrees of intestinal inflammation.